Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Abstract Text:

Immunotherapy with interferon-alpha (IFNalpha) may induce depressive symptoms, anxiety and major depression when administered for at least 1-3 months at a dose of 3-10 MUI daily, twice or three times a week. Previously, it has been shown that immunotherapy with interleukin-2 (IL-2) significantly induces the cytokine network, as measured by increases in serum IL-6, IL-10 and the IL-2 receptor (IL-2R), and that the immunotherapy-induced changes in the cytokine network are significantly correlated with the increases in depression ratings. The main aim of this study was to examine the effects of immunotherapy with IFNalpha on the cytokine network in relation to changes in depression and anxiety ratings. Fourteen patients, affected by chronic active C-hepatitis, were treated with IFNalpha (3-6 MUI s.c. three/six times a week for 6 months) and had measurements of serum IFN-gamma (IFNgamma), IL-2, IL-6, IL-6R, IL-8 and IL-10 before starting therapy and 2, 4, 16 and 24 weeks after immunotherapy with IFNalpha. Severity of depression and anxiety were measured with the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale (HAM-A), respectively. Repeated measure (RM) design ANOVAs showed significantly higher MADRS and HAM-A scores 2-4 weeks and 4-6 months after starting IFNalpha-based immunotherapy than at baseline. RM design ANOVAs showed significantly higher serum IL-6 and IL-8 levels 2-4 weeks after starting IFNalpha-based immunotherapy and higher serum IL-10 levels 2-4 weeks and 4-6 months after starting therapy than at baseline. There were significant relationships between the IFNalpha-induced changes in serum IL-6 or IL-8 and the depression and anxiety scores. The findings show that IFNalpha-based immunotherapy induces the cytokine network and that IFNalpha-induced increases in IL-6 predicts the development of depressive symptoms. Depressive symptoms following IFNalpha treatment may be secondary to cytokine induction, including that of IL-6.

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Publishing Authors By Initials

For similar persons: age groups: adult: middle aged research abstracts see: persons: age groups: adult: middle aged research

PUBMED ID PMID:

MEDLINE DATE:

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Psychiatry research

VOLUME: 105

Page Numbers: 45-55

Journal Abbreviation: Psychiatry Res

ISSN: 0165-1781

DAY: 15

MONTH: Dec

YEAR: 2001

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7911385

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Keywords Mesh Terms:

KEYWORDS: Middle Aged

MESH TERMS: adverse effects

Chemical & Substance for Abstract: Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Information

Substance Name: Interferon Alfa-2a

Registry Number: 76543-88-9

Grant and Affiliation Information for Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

AFFILIATION: Psychiatric Hospital, University 'La Sapienza', Rome, Italy.

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Psychiatry Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms Related Publications

• A new quantitative in vitro microculture method for Giardia duodenalis trophozoites.
• A plea for clinical diagnosis in present day medicine.
• A survey on biosecurity and management practices in Belgian pig herds.
• Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient.
• Alterations in immune functions during normal aging and Alzheimer's disease.
• Central serotonergic hypofunction in autism: results of the 5-hydroxy-tryptophan challenge test.
• Chemical epidemiological aspects of pesticides.
• Clinical and biological phenotype of a patient with familial glucocorticoid deficiency type 2 caused by a mutation of melanocortin 2 receptor accessory protein.
• Comparison of a computer-administered and paper-and-pencil-administered questionnaire on health and lifestyle behaviors.
• Concerns: Choosing a radiology workstation.
• Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells.
• Effects of experimental panic on neuroimmunological functioning.
• Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice.
• Functional changes across the 17-18 border in the cat.
• Identification of histamine receptors and reduction of squalene levels by an antihistamine in sebocytes.
• Immunological differences between patients with major depression and somatization syndrome.
• Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
• Interleukin-2 and schizophrenia.
• Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments.
• Parenteral and intranasal vaccination of fattening pigs against Aujeszky's disease (pseudorabies).
• Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men.
• Prevention of oxidative damage that contributes to the loss of bioenergetic capacity in ageing skin.
• Reflex sympathetic dystrophy in a renal transplant patient treated with sirolimus.
• Relationship between MHPG and anxiety.
• Scleral melting in a patient with conjunctival rhinosporidiosis.
• Slow late component in conditioned stimulus-evoked potentials from the amygdala after fear conditioning in the rat.
• Smoking in young people with asthma.
• Surface modification of gamma-Fe2O3@SiO2 magnetic nanoparticles for the controlled interaction with biomolecules.
• The optimization of magnetosandwich assays for the sensitive and specific detection of proteins in serum.
• [Hospital food: myths and realities.]